Liver Concerns Foil GLP-1 Drug; Not Enough Menopause Training; Wegovy Supply Limits

Pfizer dropped development of lotiglipron, its investigational GLP-1 receptor agonist for obesity, due to elevated liver enzymes; could other agents in the drug class carry similar risks? (Fierce Biotech)

Amazon Pharmacy plans to automatically apply manufacturers’ coupons to many insulin products to ease consumers’ price concerns. (USA Today)

But many with diabetes are still struggling to find affordable insulin. (Bloomberg Law)

Compared with men, women with diabetes carried a higher risk for developing cardiovascular disease, but these risk differences were mostly explained by obesity status and antihypertensive or statin use. (The Lancet Regional Health Europe)

A national survey of ob/gyn residency program directors found 93% strongly agreed that residents nationwide should have access to a standardized menopause curriculum that could be utilized in their programs, but only 31% said they had a menopause curriculum in their program. (Menopause)

A push to get obesity services, including drugs, covered by Medicare is underway in Congress. (The Hill)

Novo Nordisk announced plans to acquire Inversago Pharma, which has a cannabinoid receptor blocker in phase II development as a potential weight loss agent. (Reuters)

The first oral liquid diabetes medication was FDA approved for cats, Boehringer Ingelheim announced.

Novo Nordisk’s CEO said limits on U.S. supplies of semaglutide (Wegovy) will continue into next year as the company tries to keep up with demand. (Reuters)

Please enable JavaScript to view the

comments powered by Disqus.